Skip to main content
SpringerLink
Log in

Agents interfering with the platelet-vessel wall interaction

  • Congress ‘Blood and Drugs’
  • Published:
Pharmaceutisch Weekblad Aims and scope Submit manuscript

Abstract

Drugs that inhibit platelet activation may prevent thrombosis and atherosclerosis. The mechanism by which coumarins, heparin, calmodulin inhibitors, calcium entry blockers, drugs that interfere with cyclic AMP function and arachidonate metabolism, and several other compounds might achieve this protection, is discussed. Only a few of these drugs (acetylsalicylic acid, dipyridamole, sulfinpyrazone) have been tested for clinical efficacy in man. So far the results of these studies have revealed modest protection from infarction and other cardiovascular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sixma JJ. Role of blood vessel, platelet and coagulation interaction in haemostasis. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. London: Churchill Livingstone, 1981:252–67.

    Google Scholar 

  2. Packham MA, Mustard JF. Pharmacology of platelet affecting drugs. Circulation 1980;62(suppl V):26–41.

    Google Scholar 

  3. Packham MA. Platelet function inhibitors. Thromb Haemostas 1983;50:610–9.

    Google Scholar 

  4. Moncada S, ed. Prostacyclin, thromboxane and leukotrienes. Br Med Bull 1983;39:209–300.

  5. Weiss HJ. Platelets. Pathofysiology and antiplatelet drug therapy. New York: Alan R Liss, 1982:1–165.

    Google Scholar 

  6. May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis 1982;24:331–52.

    PubMed  Google Scholar 

  7. Kelton JG. Antiplatelet agents: rationale and results. Clin Haematol 1983;12:311–54.

    PubMed  Google Scholar 

  8. Gent M. The clinical evaluation of antiplatelet drugs. Recent Adv Blood Coag 1981;3:319–40.

    Google Scholar 

  9. Verstraete M. Registry of prospective clinical trials. Fifth report. Thromb Haemost 1982;48:334–8.

    PubMed  Google Scholar 

  10. Verstraete M. Registry of prospective clinical trials. Sixth report. Thromb Haemost in press.

  11. Persantine-Aspirin Reinfarction Study Research Group. Persantine and Aspirin in coronary heart disease. Circulation 1980;62:449–61.

    Google Scholar 

  12. Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980;302:250–6.

    Google Scholar 

  13. Anturane Reinfarction Italian Study Group. Sulphinpyrazone in post-myocardial infarction. Lancet 1982; 1:237–42.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, University Hospital Utrecht, Catharijnesingel 101, 3511, GV Utrecht, The Netherlands

    H. K. Nieuwenhuis & J. J. Sixma

Authors
  1. H. K. Nieuwenhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. J. Sixma
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nieuwenhuis, H.K., Sixma, J.J. Agents interfering with the platelet-vessel wall interaction. Pharmaceutisch Weekblad Scientific Edition 6, 27–31 (1984). https://doi.org/10.1007/BF01960196

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01960196

Keywords

Search

Navigation